Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Characterize the preclinical pharmacokinetics, metabolic profile, multi-species toxicology, and antitumor efficacy of azurin-p28 (NSC 745104), an amphipathic, 28 amino acid fragment (aa 50–77) of the copper containing redox protein azurin that preferentially enters cancer cells and is currently under development for treatment of p53-positive solid tumors.
An LC/MS/MS assay was developed, validated, and applied to liver microsomes, serum, and tumor cells to assess cellular uptake and metabolic stability. Pharmacokinetics was established after administration of a single intravenous dose of p28 in preclinical species undergoing chronic toxicity testing. Antitumor efficacy was assessed on human tumor xenografts. A human therapeutic dose was predicted based on efficacy and pharmacokinetic parameters.
p28 is stable, showed tumor penetration consistent with selective entry into tumor cells and significantly inhibited p53-positive tumor growth. Renal clearance, volume of distribution, and metabolic profile of p28 was relatively similar among species. p28 was non-immunogenic and non-toxic in mice and non-human primates (NHP). The no observed adverse effect level (NOAEL) was 120 mg/kg iv in female mice. A NOAEL was not established for male mice due to decreased heart and thymus weights that was reversible and did not result in limiting toxicity. In contrast, the NOAEL for p28 in NHP was defined as the highest dose (120 mg/kg/dose; 1,440 mg/m2/dose) studied. The maximum-tolerated dose (MTD) for subchronic administration of p28 to mice is >240 mg/kg/dose (720 mg/m2/dose), while the MTD for subchronic administration of p28 to Cynomolgous sp. is >120 mg/kg (1,440 mg/m2/dose). The efficacious (murine) dose of p28 was 10 mg/kg ip per day.
p28 does not exhibit preclinical immunogenicity or toxicity, has a similar metabolic profile among species, and is therapeutic in xenograft models.
- Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L (2010) A novel and rapid LC/MS/MS assay for bioanalysis of azurin p28 in serum and its pharmacokinetics in mice. J Pharm Biomed Anal 53:991–996
- Jia L, Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8:822–829 CrossRef
- Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE (2006) Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 147:476–485 CrossRef
- Jia L, Noker PE, Piazza GA, Leuschner C, Hansel W, Gorman GS, Coward LU, Tomaszewski J (2008) Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate. J Pharm Pharmacol 60:1441–1448 CrossRef
- Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM, Das Gupta TK (2004) Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 23:2367–2378 CrossRef
- Rauth S, Kichina J, Green A, Bratescu L, Das Gupta TK (1994) Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice. Anticancer Res 14:2457–2463
- Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Green A, Bratescu L, Shilkaitis A, Chakrabarty AM, Beattie CW, Das Gupta TK (2009) Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res 69:537–546 CrossRef
- Yamada T, Fialho AM, Punj V, Bratescu L, Gupta TK, Chakrabarty AM (2005) Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell Microbiol 7:1418–1431 CrossRef
- Yamada T, Hiraoka Y, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, Chakrabarty AM (2004) Apoptosis or growth arrest: modulation of tumor suppressor p53’s specificity by bacterial redox protein azurin. Proc Natl Acad Sci USA 101:4770–4775 CrossRef
- Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK (2009) A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther 8:2947–2958 CrossRef
- Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination
Cancer Chemotherapy and Pharmacology
Volume 68, Issue 2 , pp 513-524
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, 20852, USA
- 2. Samford University, Birmingham, AL, 35229, USA
- 3. Southern Research Institute, Birmingham, AL, 35205, USA
- 4. IIT Research Institute, Chicago, IL, USA
- 5. Department of Microbiology and Immunology, UIC-COM, Chicago, IL, USA
- 6. CDG Therapeutics, Chicago, IL, USA